Certificate of conformity (COC) Teraligen pills 5mg, 50pcs

Teraligen pills 5mg, 50pcs

$73.00

Active ingredient:	Alimemazine
Dosage form:	Pills
Indications for use:	Mental disorders

Add to wishlist

Categories: Medication, Neuroleptics, Neurology, psychiatry

Indications

For adults and children over 7 years of age:

As a sedative (sedative), anxiolytic (anti-anxiety), and sleep-enhancing agent:

dementia (including dementia in connection with epilepsy), occurring with symptoms of psychomotor agitation, of the affect of anxiety (as part of combination therapy);

– organic anxiety disorder (as monotherapy or in combination therapy);

– schizophrenia (with the prevalence of neurosis-like disorders, as part of combination therapy);

– mood disorders (affective disorders) in the combination therapy;

generalized anxiety disorder (as part of combination therapy);

– obsessive-compulsive disorder (as part of combination therapy);

– reaction to severe stress and adjustment disorders (acute stress reaction, post-traumatic stress disorder, unspecified reaction to severe stress, and other reactions to severe stress) in combination therapy;

and dissociative (conversion) disorder (as part of combination therapy);

– somatoform disorders (somatized distress, undifferentiated somatoform disorder hypochondriacal disorder, somatoform dysfunction of the autonomic nervous system, steady somatoform pain disorder, unspecified somatoform disorder other somatoform disorders) in combination therapy in severe anxiety or after failure of standard therapy;

– unspecified disorder of vegetative (Autonomous) nervous system and other disorders of the vegetative (Autonomous) nervous system (in combination therapy);

– anorexia nervosa (as part of combination therapy);

– emotionally unstable personality disorder (impulsive and borderline types) in the combination therapy;

– the hysterical personality disorder, anxiety (evading, avoidant) personality disorder (as part of combination therapy);

– resistant personality change after catastrophe experience (as part of combination therapy);

– hyperkinetic conduct disorder (as part of combination therapy);

– behavior disorder, limited the scope of the family (in a combination therapy after failure of standard therapy);

– nesotsializirovannyh a conduct disorder (as monotherapy or in combination therapy);

– anxiety, agitation and other symptoms and signs involving emotional state (as part of combination therapy);

– other neurotic disorders (neurosis, neurotic disorder, unspecified) in the combination therapy;

– insomnia inorganic etiology (in a combination therapy after failure of standard therapy);

– emotional disorders, which are specific to childhood (phobic anxiety disorder in children, social anxiety disorder in childhood, the disorder due to the sibling (with brothers and sisters) rivalry, unspecified emotional disorder in childhood, other emotional disorders in childhood) in the combination therapy.

As an anti-allergic agent:

– itching regardless of the location and etiology (itching of the anus, itching of the vulva, unspecified anogenital itching, itching in photocontact dermatitis and solar urticaria, dermatitis, eczema, hives, bites or Galiani non-poisonous insects or other nonpoisonous arthropods, chickenpox, measles, Hodgkin’s Disease, diabetes, shingles) as monotherapy or in combination therapy;

– asthma, hay fever, whooping cough (in the complex therapy as antiallergic drugs for the relief of cough, shortness of breath and asthma attacks);

– unspecified Allergy (as monotherapy or in combination therapy).

For children from 3 years of age:

As an anti-allergic agent:

– itching regardless of the location and etiology (itching when photocontact dermatitis and solar urticaria, dermatitis, eczema, hives, bites or Galiani non-poisonous insects or other nonpoisonous arthropods, chickenpox, measles, Hodgkin’s Disease, diabetes, shingles, itching of the anus, itching of the vulva, unspecified anogenital itching) as monotherapy or in combination therapy.

As a sedative (sedative) agent:

– during medical preparation for surgery (for the purpose of sedation before surgery).

Contraindications

– hypersensitivity to the components of the drug;

– lactose intolerance, lactase deficiency, glucose-galactose malabsorption;

– closure glaucoma;

– hyperplasia of the prostate;

– severe hepatic and/or renal failure;

– parkinsonism;

– myasthenia gravis;

– Reye’s syndrome;

– concomitant use of monoamine oxidase inhibitors (MAOIS);

– pregnancy;

– lactation period;

– children’s age up to 3 years if used as antiallergic drugs for sedation before surgery up to 7 years for other reasons.

Precautions for use

With caution, the drug should be used for alcoholism, if there is a history of complications with the use of phenothiazine-type drugs; with obstruction of the bladder neck; predisposition to urinary retention; with epilepsy; open-angle glaucoma; jaundice; suppression of bone marrow function; arterial hypotension.

Composition

One tablet contains:

active substance:

alimemazine tartrate – 5.0 mg;

excipients:

lactose monohydrate, microcrystalline cellulose, pregelatinized starch, colloidal silicon dioxide (aerosil), croscarmellose sodium, magnesium stearate.

shell composition:

Opadray II 85F34655: partially hydrolyzed polyvinyl alcohol, macrogol-3350, talc, titanium dioxide E 171, carmine red dye E 120, aluminum varnish based on sunny sunset yellow dye E 110, aluminum varnish based on indigo carmine E 132.

Composition

One tablet contains:

Active ingredient:

alimemazine tartrate-5.0 mg;

excipients:

lactose monohydrate, microcrystalline cellulose, pregelatinized starch, colloidal silicon dioxide (aerosil), croscarmellose sodium, magnesium stearate.

shell composition:

Pharmacological action

An anxiolytic agent. A sedative.

ATX code: [R06AD01].

Pharmacological properties

Pharmacodynamics

It is a phenothiazine derivative. Alimemazine acts as a mild sedative and anti-anxiety agent, has a positive effect on senestopathy, obsession and phobia. It is used for psychosomatic manifestations that develop as a result of neurovegetative disorders, vascular, traumatic and infectious disorders of the central nervous system.

The sedative effect contributes to the normalization of sleep in patients of this category. It has antiemetic and antitussive activity. Sedative and anxiolytic effects are caused by the blockade of adrenoreceptors of the reticular formation of the brain stem. The antiemetic and vegetative-stabilizing effect is due to the blockade_{of dopamine D2}-receptors of the trigger zone of the emetic center.

Due to its antihistamine activity, alimemazine is used for allergic diseases, especially of the respiratory tract, and for itching of the skin. Alimemazine is more active in antihistamines and sedatives than diprazine. The antipruritic effect is due to the effect on histamine receptors of the first type.

Pharmacokinetics

It is rapidly and completely absorbed by any route of use. The effect of alimemazine begins 15-20 minutes after use and lasts 6-8 hours. Binding to plasma proteins is 20-30%. It is metabolized in the liver. Excreted by the kidneys-70-80% in the form of a metabolite (sulfoxide).